loading

Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten

pulisher
Jun 07, 2025

Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN

Jun 07, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com

Jun 05, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire

Jun 03, 2025
pulisher
May 30, 2025

Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

May 30, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma, Inc. Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial - TipRanks

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas - BioSpace

May 29, 2025
pulisher
May 29, 2025

ESLA Stock Rating and Price Target Maintained by D. Boral Capital | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Estrella Immunopharma (ESLA) Advances in Phase I/II STARLIGHT-1 Trial | ESLA Stock News - GuruFocus

May 29, 2025
pulisher
May 05, 2025

Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World

May 05, 2025
pulisher
Apr 24, 2025

ESLA Stock: A Voyage Through Estrella Immunopharma Inc’s Finances - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com

Apr 24, 2025
pulisher
Mar 05, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace

Mar 05, 2025
pulisher
Feb 22, 2025

Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian

Feb 21, 2025
pulisher
Feb 20, 2025

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net

Feb 20, 2025
pulisher
Feb 19, 2025

Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 18, 2025
pulisher
Dec 16, 2024

Estrella Immunopharma regains Nasdaq compliance - Investing.com

Dec 16, 2024
pulisher
Nov 25, 2024

Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com

Nov 25, 2024
pulisher
Nov 14, 2024

Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St

Nov 14, 2024
pulisher
Nov 11, 2024

Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™

Nov 11, 2024
pulisher
Nov 07, 2024

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks

Nov 07, 2024
pulisher
Oct 31, 2024

Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com

Oct 31, 2024
pulisher
Oct 09, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™

Oct 09, 2024
pulisher
Oct 03, 2024

First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®

Oct 03, 2024
pulisher
Sep 27, 2024

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire

Sep 27, 2024
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):